Response rate reported for artery-delivered chemo plus checkpoint plus TKI in HCC
2015
Performing hepatic intratumoral immunotherapy since 2015
2-in-1
Artery infusion and tumor injection in one session
In plain terms
What this procedure is, without the jargon.
For cancer concentrated in the liver — most often spread from colorectal, breast or neuroendocrine tumors, or primary liver cancer — we can deliver immunotherapy through the artery that feeds the liver instead of a whole-body IV. This is intra-arterial infusion: a thin catheter is threaded, usually from the groin or wrist, into the hepatic artery, and the immune drugs are infused right where the tumors are.
In the same session we can add intratumoral immunotherapy — direct injection into the main tumor spots — so the artery delivers broad coverage across the liver while the injection targets specific foci. The goal is strong local control plus a body-wide immune response, the abscopal effect.
It is designed for liver-dominant disease that has progressed past standard treatments such as TACE (the usual bead-based liver therapy) or IV checkpoint regimens. Artery-delivered chemotherapy has well-established concentration advantages; for immunotherapy the benefit is supported by recent liver-cancer data, and we don’t claim the same numbers as chemotherapy.
Arterial delivery: a catheter concentrates the drug in the liver, sparing the rest of the body.
The treated tumor teaches your immune system to recognize the cancer body-wide.
How it works
How the procedure runs.
Part 1
Arterial access and locoregional infusion
Catheterization typically via the femoral or radial artery, with selective placement into the proper, right or left hepatic artery depending on tumor distribution. Immunotherapy agents — and in selected cases microdosed chemotherapy — are infused directly into the hepatic arterial circulation, where first-pass extraction sharply increases local concentration versus IV.
Part 2
Combined intratumoral injection
For dominant tumor foci, the same session adds intratumoral immunotherapy under CT or ultrasound guidance — combining locoregional coverage with site-specific delivery. Most patients recover the same day.
What makes it different
What this adds beyond standard hepatic infusion chemotherapy.
Standard approaches
Our approach
Floxuridine chemotherapy via an implanted pump.
Multi-agent immune cocktails plus arterial infusionin the same procedural session.
Chemotherapy mechanism only.
Chemotherapy effect plus immune engagement— two mechanisms, one visit.
Hepatic distribution only.
Hepatic distribution plus targeted intratumoral amplificationat the dominant foci.
Local control as the goal.
Local control plus systemic immune memory— the abscopal goal.
Why arterial delivery for the liver.
The liver has its own supply line
Because the liver is fed by a dedicated artery, drugs can be concentrated there and largely spared elsewhere — the pharmacologic basis of this approach.
Broad coverage plus precision
Infusion reaches disease distributed through the liver; the added injection concentrates immune stimulation at the largest tumors.
Strongest evidence base for the liver
Artery-delivered treatment for liver disease has the most published support of any locoregional site, including recent checkpoint-combination data in HCC.
Is this right for you
When this procedure is right.
This procedure is considered for:
✓Liver-dominant metastatic colorectal cancer beyond first or second line
✓Hepatocellular carcinoma beyond TACE and beyond atezolizumab + bevacizumab or durvalumab + tremelimumab
✓Liver-dominant breast cancer metastases
✓Liver-dominant neuroendocrine tumors
✓Liver-dominant melanoma metastases
✓Patients seeking locoregional immunotherapy delivery rather than IV checkpoint blockade
“Liver-dominant disease is one of the most actionable contexts for locoregional immune approaches. If the disease lives in one organ, that is where the immune stimulation should be concentrated.”
— Dr. Jason R. Williams
Track record
Pioneering arterial immunotherapy.
2015
Hepatic intratumoral Yervoy / Opdivo
Early direct-injection work in the liver — the proving ground for AblationVax.
2024–2026
Evidence base strengthens
Artery-delivered chemotherapy with checkpoint inhibitors and TKIs shows substantial response rates in HCC.
Now
Infusion plus injection in one session
Locoregional coverage combined with targeted intratumoral amplification.
Ready to move forward?
There is more ahead. Take the next step with confidence.
Complimentary evaluation.
Dr. Williams’ team will personally review your case and imaging — no cost, no obligation.
